A. Kargi Et Al. , "IL8 and Serum Soluble TRAIL Levels Following Anti-VEGF Monoclonal Antibody Treatment in Patients with Metastatic Colon Cancer," CLINICAL LABORATORY , vol.58, pp.501-505, 2012
Kargi, A. Et Al. 2012. IL8 and Serum Soluble TRAIL Levels Following Anti-VEGF Monoclonal Antibody Treatment in Patients with Metastatic Colon Cancer. CLINICAL LABORATORY , vol.58 , 501-505.
Kargi, A., Yalcin, A. D., ERİN, N., Savas, B., Polat, H. H., & Gorczynski, R. M., (2012). IL8 and Serum Soluble TRAIL Levels Following Anti-VEGF Monoclonal Antibody Treatment in Patients with Metastatic Colon Cancer. CLINICAL LABORATORY , vol.58, 501-505.
Kargi, Aysegul Et Al. "IL8 and Serum Soluble TRAIL Levels Following Anti-VEGF Monoclonal Antibody Treatment in Patients with Metastatic Colon Cancer," CLINICAL LABORATORY , vol.58, 501-505, 2012
Kargi, Aysegul Et Al. "IL8 and Serum Soluble TRAIL Levels Following Anti-VEGF Monoclonal Antibody Treatment in Patients with Metastatic Colon Cancer." CLINICAL LABORATORY , vol.58, pp.501-505, 2012
Kargi, A. Et Al. (2012) . "IL8 and Serum Soluble TRAIL Levels Following Anti-VEGF Monoclonal Antibody Treatment in Patients with Metastatic Colon Cancer." CLINICAL LABORATORY , vol.58, pp.501-505.
@article{article, author={Aysegul Kargi Et Al. }, title={IL8 and Serum Soluble TRAIL Levels Following Anti-VEGF Monoclonal Antibody Treatment in Patients with Metastatic Colon Cancer}, journal={CLINICAL LABORATORY}, year=2012, pages={501-505} }